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Kidney transplant monitoring by 
urinary flow cytometry: Biomarker 
combination of T cells, renal tubular 
epithelial cells, and podocalyxin-
positive cells detects rejection
nina Goerlich1,6*, Hannah Antonia Brand1,6, Valerie Langhans1, Sebastian Tesch1, 
thomas Schachtner2, Benjamin Koch3, Alexander paliege4, Wolfgang Schneider1, 
Andreas Grützkau5, Petra Reinke1 & philipp enghard1
Creatinine and proteinuria are used to monitor kidney transplant patients. However, renal biopsies are 
needed to diagnose renal graft rejection. Here, we assessed whether the quantification of different 
urinary cells would allow non-invasive detection of rejection. Urinary cell numbers of CD4+ and CD8+ 
T cells, monocytes/macrophages, tubular epithelial cells (TEC), and podocalyxin(PDX)-positive cells 
were determined using flow cytometry and were compared to biopsy results. Urine samples of 63 
renal transplant patients were analyzed. Patients with transplant rejection had higher amounts of 
urinary T cells than controls; however, patients who showed worsening graft function without rejection 
had similar numbers of T cells. T cells correlated with histological findings (interstitial inflammation 
p = 0.0005, r = 0.70; tubulitis p = 0.006, r = 0.58). Combining the amount of urinary T cells and TEC, or T 
cells and PDX+ cells, yielded a significant segregation of patients with rejection from patients without 
rejection (all p < 0.01, area under the curve 0.89–0.91). Urinary cell populations analyzed by flow 
cytometry have the potential to introduce new monitoring methods for kidney transplant patients. 
The combination of urinary T cells, TEC, and PDX-positive cells may allow non-invasive detection of 
transplant rejection.
Although kidney transplantation is the most favorable therapy for end stage renal disease, the risk of rejection 
remains a constant concern1. Allograft rejection leads to a high risk of graft dysfunction, accompanied by a signif-
icantly higher probability of chronic failure and graft loss2–4. Cellular rejection and humoral rejection have been 
described to severely impair transplant function and worsening survival prognosis2.
Currently, renal transplant function is mainly monitored using creatinine and proteinuria. However, these are 
only mediocre discriminators for the different renal transplant pathologies. Renal transplant biopsy remains the 
gold standard for diagnosing transplant rejection, but its use is limited due to its invasive nature. Novel biomark-
ers hold promise in monitoring different aspects of renal transplant pathology non-invasively, thereby allowing 
for early detection of transplant rejection and for adjustments in treatment.
In recent years, there has been a tremendous effort to identify novel biomarkers for transplant rejection, 
including urinary cytokines, binding receptors, proteomics, and genomics5–7. However, so far, none of the 
assessed biomarkers has shown the desired sensitivity and specificity.
Different cells present in the urine may be used as biomarkers, since they likely reflect cellular changes in the 
transplant and are arguably less variable than upstream inflammatory-signal biomarkers. We have previously 
reported that urinary T cells analyzed by flow cytometry are an excellent biomarker for intrarenal inflammation8. 
Other groups have already reported on urinary immune cells9, including different T cell subsets analyzed with 
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flow cytometry as biomarkers for transplant rejection, with promising results9–12. Besides immune cells, the detec-
tion of tubular epithelial cells (TEC)9,10 and podoctyes13–15 have been reported as biomarkers, using urinary sed-
iments in different renal diseases.
Here we hypothesize that cellular signatures of different urinary cells will reflect different elements of the 
renal transplant pathology. Specifically, assuming that T cells and monocytes/macrophages will reflect intra-
renal inflammation; TEC will indicate tubular damage; and podocytes, specifically podocalyxin-positive 
(PDX-positive) cells, will mirror glomerular pathology, we are interested to know whether the combination 
of these cells would allow a more precise, non-invasive differentiation of renal transplant rejection from other 
transplant pathologies, as compared to monitoring only singular cell subsets. In this study, we analyze urinary 
cell populations of CD4+ and CD8+ T cells, monocytes/macrophages, TEC, and PDX-positive cells to evaluate 
correlations with respect to allograft rejection vs. non-rejection. The overall goal of this analysis is to establish a 
non-invasive diagnostic tool to monitor kidney transplant patients.
Results
Urinary tubular epithelial cells and podocalyxin-positive cells can be detected by flow cytometry. 
Urinary TEC were detected using a pan-cytokeratin reactive antibody as lineage marker for epithelial cells, 
CD10 (also called neutral endopeptidase, NEP, CALLA) as a marker for TEC originating in the proximal tubular 
system16,17 and epithelial cell adhesion molecule (EPCAM) as a marker for distal TEC18,19. Therefore, proximal 
urinary TEC were defined as cytokeratin and CD10 positive cells, and distal TEC as cytokeratin and EPCAM 
positive cells. Urinary podocalyxin positive cells were analyzed as a surrogate for urinary podocytes. Specificity 
of the antibody binding was demonstrated using matching isotype controls (Fig. 1).
Urinary cell composition varies between different graft pathologies. Urine samples of 39 patients 
with graft deterioration were analyzed by flow cytometry for immune cell populations, PDX-positive cells, and 
Figure 1. Establishment of a staining assay using human kidney tissue to analyze tubular epithelial cells and 
podocalyxin-positive cells by flow cytometry. (A) Kidney tissue staining. Human kidney tissue from deceased 
patients was used to establish an applicable antibody panel. TEC biomarker Cytokeratin (intracellular) (grey: 
unstained, blue: Cytokeratin). Cytokeratin+ cells were used to differentiate between proximal (CD10+, blue) and 
distal (EPCAM+, blue) TEC; Isotype controls (grey). Podocytes stained with PDX and PDX isotype. (B) Urinary 
isotype controls for TEC and podocytes. Cytokeratin+ (intracellular) TEC stained with CD10 and EPCAM; 
isotype controls for cytokeratin, CD10 and EPCAM. Podocytes stained with PDX and PDX-Isotype. TEC, 
tubular epithelial cells; PDX, podocalyxin; EPCAM, epithelial cell adhesion molecule.
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TEC. According to the histological diagnosis of the renal biopsy, 14 patients had T cell-mediated rejection, 7 
patients had antibody-mediated rejection, and 18 patients had no signs of rejection (representative biopsy pic-
tures are depicted in Fig. 2). Five patients had inconclusive biopsies and were excluded from the analysis. As 
shown in Fig. 3, overall urinary cell quantity varied between the described groups. Different cell types were 
compiled for each group in planet plots: The highest total cell number was found in biopsy patients without 
rejection (No RX). In these patients, urinary cells consisted mainly of monocytes/macrophages and TEC. The 
largest T cell population was found in patients with T cell mediated rejection (TCMR). Patients with proven 
antibody-mediated rejection (ABMR) had the lowest total cell number, as well as the lowest cell numbers in all 
different cell types.
Urinary TEC, PDX-positive cells, and T cells did not correlate with dipstick results for hemoglobin, protein, 
or leukocytes.
Correlation of different urinary cell populations with histopathological lesions. To assess our 
hypothesis that different urinary cell populations reflect specific renal pathologies, we examined the correlations 
of patients’ urinary numbers with the respective histopathological findings, using the BANFF classification of 
201320, which was the most recent at the time of the described analysis (Fig. 4).
As predicted, urinary T cells correlated with levels of interstitial inflammation (p = 0.0005, r = 0.7) and tubu-
litis (p = 0.006, r = 0.58). Furthermore, T cells negatively correlated with chronic transplant glomerulopathy 
(p = 0.0235, r = −0.43).
Urinary PDX-positive cells correlated with the histological scores of glomerular injury; however, this corre-
lation was unexpectedly negative. In detail, the quantity of urinary PDX-positive cells negatively correlated with 
chronic glomerulopathy score (p = 0.0451, r = −0.4) and glomerulitis (p = 0.0322, r = −0.41), and this correla-
tion was mainly driven by high podocyte counts in patients with a score of 0 in the respective BANFF elements.
Urinary TEC negatively correlated with glomerulitis (CD10+ TEC: p = 0.02, r = −0.44; EPCAM+ TEC: 
p = 0.0026, r = −0.56) and with chronic transplant glomerulopathy (CD10+ TEC: p = 0.0072, r = −0.51; 
EPCAM+ TEC: p = 0.0006, r = −0.63).
Peritubular capillaritis did not correlate with T cells, PDX+ cells or TEC.
Total amounts of urinary immune cells, tubular epithelial cells, and podocalyxin-positive cells 
only moderately separate patients with rejection. Next, we assessed whether certain subsets of uri-
nary cells would allow non-invasive detection of acute graft rejection. To this end, we also included a further 
control group of 24 patients with stable renal graft function without renal biopsy.
In patients with TCMR, significantly higher amounts of immune cells were observed for CD3+CD8+ and 
CD3+CD4+ T cells (p < 0.05), compared to patients with ABMR. Although the T cells tended to be higher in 
the TCMR group compared to No RX group, there was no good separation of these groups and no significant 
difference. Unexpectedly, the patients with No RX had significantly higher urinary counts of PDX-positive cells, 
proximal TEC, and distal TEC than patients with TCMR (p < 0.01) or ABMR (p < 0.01 for PDX-positive cells, 
p < 0.001 for CD10+ TEC, p < 0.01 for EPCAM+ TEC) (Fig. 5).
The control (Ctrl) group consisting of patients with stable renal graft function had significantly lower 
CD3+CD8+ (p < 0.001), CD3+CD4+ (p < 0.01) T cell, and monocytes/macrophage (p < 0.01) counts than 
TCMR patients (Fig. 5). Compared to the No RX group, patients in the Ctrl group showed lower cell amounts of 
CD3+CD8+ T cells (p < 0.01), monocytes/macrophages (p < 0.01), and TEC (CD10+ TEC p < 0.0001; EPCAM+ 
TEC: p < 0.001). Like patients with No RX, the Ctrl group showed higher cell counts than the patients with 
ABMR with respect to the PDX+ cells (p < 0.05) and EPCAM+ TEC (p < 0.05).
Increased proportions of T cells per tubular epithelial cells and T cells per podocalyxin-positive 
cells in patients with allograft rejection. As the different patient groups showed different patterns of 
cells in their urine, we next assessed whether a combination of certain cell subsets would increase the diagnostic 
yield (Fig. 6). Calculating the ratios of all T cells per TEC, patients with TCMR or ABMR showed a significantly 
higher ratio compared to the patients with No RX (p < 0.01). No significant difference was observed between 
patients with TCMR and ABMR.
Similarly, when normalizing the amount of urinary T cells to the amount of PDX-positive cells, a signifi-
cantly higher ratio was observed in patients with rejection (TCMR or ABMR) than in patients without rejection 
(p < 0.01). Again, no significant difference was observed between patients with TCMR and ABMR.
Calculating ROC curves, we observed a good segregation of patients with rejection (T cell-mediated or 
antibody-mediated) from patients who had graft deterioration without rejection (AUC 0.90 for T cells/TEC total, 
AUC 0.89 for T cells/CD10+ TEC, AUC 0.91 for T cell/ECPAM+ TEC, AUC 0.89 for T cells/PDX-positive cells).
Discussion
Kidney allograft rejection is a constant concern in renal transplant patients. Hence, non-invasive biomarkers that 
can help in monitoring kidney transplant patients and identify rejection are of great interest. Here, we assessed 
whether the quantification of urinary immune cells, TEC, and PDX-positive cells would allow non-invasive allo-
graft rejection. While the single subsets of urinary cells showed only modest separation of patients with and with-
out rejection, the combination of urinary T cells, TEC, and PDX-positive cells allowed non-invasive detection of 
patients with acute rejection.
Urinary T cells detected by flow cytometry have been described in various renal diseases and seem to directly 
reflect renal inflammation, making them a promising biomarker21–23. Several groups have assessed urinary T cells 
as a biomarker for renal transplant rejection and have reported elevated T cells in patients with acute rejection9–12. 
However, urinary T cells alone have not consistently delineated patients with and without rejection in all studies. 
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Figure 2. Representative figures of renal biopsies matched with flow cytometry. (A) Patient with borderline 
lesions suspicious for TCMR, A.1 and A.2 HE, A.3 PAS, A.4. Flow cytometry analysis of T cells. (B) Patient 
with TCMR, B.1–B.3 HE, B.4 Flow cytometry analysis of T cells. (C) Patient with ABMR, C.1 and C.2 HE, 
C.3 Jones’ stain, C.4 Flow cytometry analysis of T cells. (D) Patient with ABMR, D.1 PAS, D.2 HE, D.3 Jones’ 
stain, D.4 Flow cytometry analysis of T cells. (E–H) Patients without rejection, but diverse pathologies. E.1 and 
H.1 PAS, F.1 and G.1 HE, E.2, F.2, G.2, H.2 Flow cytometry analysis of T cells. No RX, no rejection; TCMR, T 
cell-mediated rejection; ABMR, antibody-mediated rejection; HE, Hematoxylin and eosin stain; PAS, Periodic 
acid–Schiff reaction.
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Therefore, we analyzed whether combining urinary T cells with urinary monocytes/macrophages, TEC, and 
PDX-positive cells might increase the diagnostic yield of urinary cells in the transplant setting.
Recent research has shown that renal epithelial cells express cytokeratin as stress responders and potential 
biomarkers24,25. In order to distinguish proximal from distal TEC, we used CD10 and EPCAM as they were 
described by previous authors16–19. By combining these markers, we were able to establish detection of urinary 
proximal and distal TEC.
Figure 3. Urinary cell populations in patients with graft deterioration and renal biopsy. (A) Urinary T cells, 
monocytes/macrophages, PDX-positive cells and TEC in a patient with suspected graft rejection analyzed by 
flow cytometry. The dot plots show a representative gating strategy. (B) Patients were allocated to the No RX, 
TCMR or ABMR group according to the histological diagnosis and a control group of stable kidney transplant 
patients was analyzed. Planet plots illustrating proportions of urinary cell populations in the analyzed groups. 
Planet rings are proportional to the standard deviation. (C) Subdivision of events (Mean) measured by flow 
cytometry. SSC – side scatter; FSC – forward scatter; PDX, podocalyxin; EPCAM, epithelial cell adhesion 
molecule; TEC, tubular epithelial cells; No RX, no rejection; TCMR, T cell-mediated rejection; ABMR, 
antibody-mediated rejection.
Figure 4. Correlation of urinary cell numbers with histopathological BANFF Classification of 2013. Urinary 
T cells, TEC and PDX+ cells in kidney transplant patients with allograft deterioration. T cell counts correlate 
with interstitial inflammation and tubulitis. T cell counts negatively correlate with chronic transplant 
glomerulopathy. TEC and PDX+ cells negatively correlate with chronic transplant glomerulopathy and 
glomerulitis. PDX, podocalyxin; EPCAM, epithelial cell adhesion molecule; TEC, tubular epithelial cells.
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Urinary podocyte-associated molecules have been reported as a biomarker for various renal diseases26–28. 
Podocalyxin is a surface antigen of podocytes and regulates cell adhesion and morphology29. Podocyte damage 
is supposed to be accompanied by podocyte detachment. Their sheds and fragments are found in the urine as 
podocalyxin-positive elements13. However, podocalyxin is not exclusively expressed by podocytes and therefore 
is not a specific marker30. Furthermore, while staining for TEC and urinary immune cells did allow for identifi-
cation of circumscribed cell populations (at least in patients with increased amounts), staining for podocalyxin 
was challenging and did not result in the identification of a clear cell population. Therefore, the cell population 
referred to as PDX-positive in this paper should not be assumed to be a pure podocyte population and must be 
interpreted as podocytes with caution.
Assuming that a renal graft rejection induces destruction and detachment of TEC and podocytes, we were sur-
prised to find the largest cell populations in patients without rejection. At least for podocytes, increased shedding 
after renal transplantation has been reported before, potentially due to podocyte stress31. In patients receiving 
renal biopsy, as expected, the amount of urinary T cells correlated with the histological element, thus reflecting 
inflammation. However, counter to our prediction, the amount of TEC did not reflect the tubular or glomerular 
damage observed in the biopsy, whereas PDX-positive cells did negatively correlate with chronic transplant glo-
merulopathy and glomerulitis. The significance of the high amounts of TEC and PDX-positive cells observed in 
patients without graft rejection is presently unclear.
In clinical practice, non-invasive detection of graft rejection would enable early diagnosis and would poten-
tially facilitate monitoring and tailoring of the patient’s immunosuppression. Considering that patients without 
rejection showed high numbers of TEC and PDX-positive cells but low numbers of T cells, we identified a com-
bination of biomarkers as a non-invasive tool for kidney transplant evaluation: the ratio of T cells to TEC or to 
PDX-positive cells seems capable of distinguishing humoral and acute rejection from no rejection. Specifically, 
the clearest distinction was achieved by considering the ratio of T cells per EPCAM+ TEC (AUC = 0.91). Whether 
these results can be confirmed in an independent study and can be used to assess treatment responses remains to 
be determined.
In summary, here we report flow cytometry monitoring of urinary cell populations as a potential method for 
monitoring kidney transplant patients. Increased amounts of T cells in the urine of patients with rejection sup-
port our previous assumption that urinary immune cells mirror intrarenal inflammation. Unexpectedly, urinary 
TEC and PDX-positive cells did not reflect damage in the respective compartments, and the significance of their 
Figure 5. Urinary cell numbers in patients with graft deterioration and renal biopsy. Biopsies of patients with 
suspected graft rejection were analyzed histologically. Patients were subdivided into three groups according 
to the diagnosis. A separate group of graft patients with stable renal function not receiving a biopsy is also 
displayed. Hollow dots symbolize renal biopsies, which were excluded from calculation due to inadequate 
sample material but did show a suggestive result. *p < 0.05, **p < 0.01 ***p < 0.001 ****p < 0.0001. EPCAM, 
epithelial cell adhesion molecule; TCMR, T cell-mediated rejection; ABMR, antibody-mediated rejection; No 
RX, no rejection; Ctrl, control group.
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presence in urine is presently unknown. Combining counts of urinary T cells, TEC, and PDX-positive cells, 
however, may provide a useful biosignature for non-invasive detection of renal graft rejection in clinical routine.
Materials and Methods
Patients and controls. Urine samples from 63 renal transplant patients were collected and analyzed for 
urinary cell populations utilizing flow cytometry. Detailed patient characteristics are displayed in Tables 1 and 
2, individual immunosuppression details are included as supplemetary information. Of these patients, 39 were 
admitted due to renal allograft deterioration and underwent renal biopsy as a standard procedure for diagnosing 
allograft rejection (biopsy cohort). Urine was collected within three days before or after the biopsy.
The current study divided these patients into three groups according to their histological diagnosis: patients 
who had been classified as affected by acute cellular rejection were considered the TCMR group; patients with 
proven acute or chronic humoral rejection constituted the ABMR group; and samples without rejection were 
classified as the No RX group.
Patients with uncertain histological diagnosis due to insufficient biopsy material were excluded from the anal-
ysis; however, they are displayed here as separate data points within the diagnostic categories suggested by their 
respective renal pathologists. Meanwhile, a handful of particular diagnoses excluded biopsy patients from this 
study: membranous glomerulonephritis, urinary tract infection, allergic interstitial nephritis, focal segmental 
glomerulosclerosis, and recurrent IgA nephropathy.
An additional cohort of 24 transplant patients with stable graft function was analyzed as a control group. 
Stable graft function was defined by stable serum creatinine (fluctuations less than 25%) or creatinine decrease on 
regular outpatient clinic visits, and no admittance related to issues regarding kidney transplant function during 
the 6 months prior to urine analysis. Of these, 6 cases deserve special mention. One control patient showed an 
elevation in creatinine 1 month prior to analysis, which resolved within 1 week; the creatinine elevation was of 
unclear significance. Furthermore, in 5 patients with long-stable transplant function (median years after trans-
plant = 8.39), creatinine had not been measured 6 months prior to urine analysis because outpatient visits were 
scheduled less frequently; nonetheless, these 5 patients met the criteria of stable creatinine and absence of hospital 
admittance. All 6 of these cases remained in the Ctrl group.
Urine collection started in March 2016 and ended in March 2017. Samples were collected from patients of 
the Department of Nephrology, Charité University Hospital, Berlin. Informed consent was obtained from all 
patients for study participation. Furthermore, Patients agreed and gave written consent to participate and to the 
Figure 6. Ratios and ROC curves of urinary cell populations in renal transplant patients with allograft 
deterioration. (A) Patients were allocated to the No RX, TCMR, or ABMR group according to the histological 
diagnosis. The control group Ctrl includes transplant patients without clinical graft deterioration. Ratios are 
distinct across patients with TCMR, ABMR, No RX, and the control group. Hollow dots symbolize renal 
biopsies excluded from calculation due to inadequate sample material but did show a suggestive result. (B) ROC 
curves for biomarker combination of T cells, PDX+ cells, CD10+ TEC, and EPCAM+ TEC. The comparisons 
are TCMR and ABMR against No RX (black), and TCMR and ABMR against No RX and Ctrl (gray). *p < 0.05, 
**p < 0.01 ***p < 0.001 ****p < 0.0001. ROC, receiver operating characteristic; AUC, area under the curve; 
TCMR, T cell mediated rejection; ABMR, antibody-mediated rejection; No RX, no rejection; Ctrl, control 
group.
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publication of the findings in a scientific journal. Moreover, our method of biomarker staining was tested on 
kidney tissue harvested postmortem from deceased patients with the consent of their relatives for postmortem 
donation of a small kidney sample for research purpose. The Charité University review board granted ethical 
approval (Charité EA1/152/16 and EA 2/045/18), and the study was conducted according to the ethical guidelines 
both at our institution and of the Helsinki Declaration.
Establishment of a method for detecting tubular epithelial cells and podocalyxin-positive cells 
via flow cytometry by staining kidneys from deceased patients. To establish a staining protocol for 
the urinary detection of proximal TEC, distal TEC, and PDX-positive cells, human kidneys donated by deceased 
individuals were digested within 24 hours after death and used. Tissue was digested in RPMI medium containing 
collagenase VIII and DNase for 30–60 minutes at 37 °C. Red blood cell lysis was performed by BD Pharm Lyse 
(BD, Franklin Lakes, NJ, USA). Following this, cells were stained with viability dye and separated into dead and 
living cells. Staining protocol and flow cytometry analysis were equal, as described below.
Staining and flow cytometry. Within 8 hours after collection, a urine dipstick test for each sample was 
performed (Only nitrite-negative samples were used for analysis.), and urine samples were centrifuged (280 × g, 
4 °C, 8 minutes). The pellet was resuspended in phosphate-buffered saline (PBS)/bovine serum albumin (BSA). 
Prior to the staining, peripheral blood monoclonal cells were isolated using Ficoll-Paque (Density 1.073 g/mL, 
Characteristic T cell-mediated rejection (TCMR) Antibody-mediated rejection (ABMR) No rejection in biopsy (No RX) Control group
Mean age ± SD 49 (±18) 58 (±18) 56 (±13) 47 (±14)
Female/Male 4/10 1/6 6/12 10/14





















2x ADPKD, 2x unknown
4x ADPKD, 2x IgA nephropathy,
2x reflux nephropathy,















2x no specific treatment
1x methylprednisolone,
1x cyclophosphamide,




3x no specific treatment
4x methylprednisolone,
1x anti-thymocyte globulin,
13x no specific treatment
—
Basic immuosuppression
4x tacrolimus + mycophenolate + prednisone,  
5x tacrolimus + mycophenolate +  
methylprednisolone,  
3x tacrolimus + mycophenolate,
1x tacrolimus, 1x cyclosporine
3x tacrolimus + mycophenolate,
1x mycophenolate + cyclosporine,
1x tacrolimus + mycophenolate +  
prednisone,
1x everolimus + mycophenolate +  
methylprednisolone,
1x tacrolimus + mycophenolate +  
methylprednisolone
9x tacrolimus + mycophenolate +  
methylprednisolone,
4x tacrolimus + mycophenolate +  
prednisone,
2x tacrolimus + mycophenolate,
1x mycophenolate + cyclosporine,
1x tacrolimus + everolimus +  
methylprednisolone,
1x tacrolimus + azathioprine +  
methylprednisolone
9x tacrolimus + mycophenolate + 
 methylprednisolone, 9x 
tacrolimus + mycophenolate,
3x mycophenolate + cyclosporine, 
1x everolimus + mycophenolate, 1x 
mycophenolate + prednisone, 1x none
Level of steriods
2x methylprednisolone 8 mg,
3x methylprednisolone 4 mg,
1x prednisone 125 mg,
1x prednisone 24 mg,
1x prednisone 5 mg,
1x prednisone 4 mg
1x methylprednisolone 4 mg,
1x methylprednisolone 2 mg,
1x prednisone 2 mg
9x methylprednisolone 4 mg,
1x methylprednisone 8 mg,
1x methylprednisolone 24 mg,
1x prednisone 2.5 mg,
1x prednisone 4 mg,
1x prednisone 7.5 mg,
1x prednisone 250 mg
1x methylprednisolone 10 mg, 1x 
methylprednisolone 8 mg,
4x methylprednisolone 4 mg,
3x methylprednisolone 2 mg,
1x prednisone 5 mg
CNI Level median (range) 7.90 (9.74) ng/ml 5.6 (0.7) ng/ml 13.97 (21.6) ng/ml 6.19 (11.86) ng/ml
GFR median (range) DoA 23.57 (77) ml/min/1.73 m² 21.28 (32) ml/min/1.73 m² 23.61 (54) ml/min/1.73 m² 53.34 (93) ml/min/1.73 m²
Creatinine median (range) DoA 7.82 (44.95) mg/dl 3.1 (2.39) mg/dl 3.66 (10.14) mg/dl 1.54 (3.39) mg/dl
Urea median (range) 95.37 (208.8) mg/dl 133.71 (96) mg/dl 105.33 (165) mg/dl 57 (119) mg/dl
Urinary protein-creatinine ratio median 
(range) DoA 547.48 (1807.6) mg/g creatinine 1357.2 (1918) mg/g creatinine 1523.44 (4588) mg/g creatinine 426.42 (4298) mg/g creatinine
Urine volume ± SD 111 (±39) ml 120 (±50) ml 84 (±45) ml 76 (±34) ml
Proteinuria median (range) 30 (100) mg/dl 65 (300) mg/dl 22.5 (2000) mg/dl 0 (100) mg/dl
Leucocyturia median (range) 0 (125) WBC/μl 0 (0) WBC/μl 0 (70) WBC/μl 0 (70) WBC/μl
Erythrocyturia median (range) 200 (200) RBC/μl 5 (200) RBC/μl 80 (200) RBC/μl 0 (80) RBC/μl
Days after transplant median (range) 66.5 (9524) 3368 (1833) 105 (5970) 2067 (7349)
Table 1. Patient Characteristics. Demographic and medical details of kidney transplant patients and rejection 
therapy. Treatment of rejection started 5 days before and continued for up to 19 days after biopsy. SD, standard 
deviation; WBC, white blood cell count; RBC, red blood cell count; DoA, Day of Analysis.
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Sigma-Aldrich, Hamburg, Germany). Fixation with 2% paraformaldehyde was performed for the staining of TEC 
and podocytes. The following monoclonal antibodies and conjugates were used for staining: CD3-PerCP (Clone: 
BW264/56, Isotype mouse IgG2), CD4-PE-Vio770 (Clone: VIT4, Isotype mouse IgG2a), CD8-APC-Vio770 
(Clone: 135/80, Isotype mouse IgG2), CD45RO-VioGreen (Clone: 5B1, Isotype mouse IgG2), CD36-PE (AC106, 
Isotype mouse IgG2a), CD14-FITC (Clone: TÜK4, Isotype: mouse IgG2), Cytokeratin-FITC (Clone: CK3-6H5, 
Isotype: mouse IgG1), CD10-PE-Vio770 (Clone: 97C5, Isotype: Mouse IgG1), EPCAM-APC-Vio770 (Clone: 
HEA-125, Isotype: mouse IgG1), Podocalyxin-PE (Clone: REA246) (all Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany), Alexa Fluor 647 anti-cytokeratin-FITC (Clone: C-11, Isotype: Mouse IgG1) (BioLegend, 
San Diego, USA).
Cells were incubated with antibody cocktails for 15 minutes at 4 °C in the dark. PBS/BSA containing 10% 
human IgG (Flebogamma; Grifols, Langen, Germany) was utilized to block unspecific binding. In addition, 
Saponin (S7900 Sigma-Aldrich, Hamburg, Germany) was used for intracellular staining of cytokeratin (0.25 g 
in 50 ml PBS). Immediately before flow cytometric analysis, 4′,6-Diamidine-2′-phenylindole dihydrochloride 
(DAPI) (Sigma-Aldrich, Hamburg, Germany) was added to exclude dead cells (only for unfixed samples). Cell 
numbers were calculated and normalized to a volume of 100 mL urine. Samples were analyzed using a MACS 
Quant Analyzer (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Datasets were analyzed using FlowJo 
10.3 (Tree Star, Ashland, Oregon, USA).
Statistical analysis. In consideration of this trial as an exploratory study, the Mann-Whitney test was used 
to calculate differences in urinary cell populations. For all tests, the significance threshold is set at p < 0.05. All 
medians, means, Mann-Whitney tests, receiver operating characteristic (ROC) curves, and Spearman correla-
tions were calculated using GraphPad Prism 5 (GraphPad Software, San Diego, California, USA). The formula 
for the creation of planet plots was root (Mean/3.14)*2 for the planet’s size and root ((Mean + standard devi-
ation))/3.14)*2 for the size of the ring (the ellipse, representing the standard deviation). Adobe Illustrator CC 
(Adobe Systems Incorporated, San Jose, California, USA) was used for presentation of planet plots.
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